EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Delta-9-Tetrahydrocannabinol and Cannabidiol Drug-Drug Interactions

Paul T Kocis, Kent E Vrana

Medical Cannabis and Cannabinoids · 07.07.2020 · 3 (1) · 61-73

DOI: 10.1159/000507998 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Medical Cannabis and Cannabinoids, online erschienen am 07.07.2020. Verfasst von Paul T Kocis und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Penn State Health, Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA. Die Arbeit wurde bisher 73-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although prescribing information (PI) is often the initial source of information when identifying potential drug-drug interactions, it may only provide a limited number of exemplars or only reference a class of medications without providing any specific medication examples. In the case of medical cannabis and medicinal cannabinoids, this is further complicated by the fact that the increased therapeutic use of marijuana extracts and cannabidiol oil will not have regulatory agency approved PI. The objective of this study was to provide a detailed and comprehensive drug-drug interaction list that is aligned with cannabinoid manufacturer PI. The cannabinoid drug-drug interaction information is listed in this article and online supplementary material as a PRECIPITANT (cannabinoid) medication that either INHIBITS/INDUCES the metabolism or competes for the same SUBSTRATE target (metabolic enzyme) of an OBJECT (OTHER) medication. In addition to a comprehensive list of drug-drug interactions, we also provide a list of 57 prescription medications displaying a narrow therapeutic index that are potentially impacted by concomitant cannabinoid use (whether through prescription use of cannabinoid medications or therapeutic/recreational use of cannabis and its extracts).

Schlagwörter

Stichwörter der Autor:innen

CannabidiolCannabisCytochrome P450Drug-drug interactionsMedical marijuanaMetabolismTetrahydrocannabinol

Autor:innen und Institutionen

  • Department of Pharmacy, Penn State Health, Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA.
  • Department of Pharmacology, Penn State College of Medicine, Hershey, Pennsylvania, USA.

Zitieren

APA

Kocis, P. T., & Vrana, K. E. (2020). Delta-9-Tetrahydrocannabinol and Cannabidiol Drug-Drug Interactions. Medical Cannabis and Cannabinoids, 3(1), 61-73. https://doi.org/10.1159/000507998

Vancouver

Kocis PT, Vrana KE. Delta-9-Tetrahydrocannabinol and Cannabidiol Drug-Drug Interactions. Medical Cannabis and Cannabinoids. 2020;3(1):61-73. doi:10.1159/000507998

BibTeX
@article{Kocis2020,
  author = {Kocis, Paul T and Vrana, Kent E},
  title = {Delta-9-Tetrahydrocannabinol and Cannabidiol Drug-Drug Interactions},
  journal = {Medical Cannabis and Cannabinoids},
  year = {2020},
  volume = {3},
  number = {1},
  pages = {61--73},
  doi = {10.1159/000507998}
}
Kostenlos starten →